



## Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs and Co-Founders of Amylyx, will present at the 11<sup>th</sup> Annual SVB Leerink Global Healthcare Conference. The conference is being conducted in a virtual format, and the presentation will take place on Thursday, February 17, 2022 at 4:20pm ET.

A live webcast of the presentation can be accessed under "Events" in the Investor section of the Company's website, <https://investors.amylyx.com/news-events/events>, and will be available for replay for 90 days following the event.

### About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. For more information, visit [www.amylyx.com](http://www.amylyx.com) and follow us on [LinkedIn](#) and [Twitter](#). For investors, please visit [www.investors.amylyx.com](http://www.investors.amylyx.com).

### Media

Becky Gohsler  
Finn Partners  
(646) 307-6307  
[Becky.Gohsler@finnpartners.com](mailto:Becky.Gohsler@finnpartners.com)

### Investors

Lindsey Allen  
Amylyx Pharmaceuticals, Inc.  
(857) 320-6244  
[investors@amylyx.com](mailto:investors@amylyx.com)

Source: Amylyx Pharmaceuticals, Inc.